Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.31 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.31 |
| ▸ | HTR1B | P28222 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29335016 | 0.83 | NOS3 (0.35) | NOS3NOS1NOS2P2RX3P2RX2 | |
| SCHEMBL29335014 | 0.80 | NOS3 (0.39) | NOS3NOS1NOS2P2RX3P2RX2 | |
| SCHEMBL29333356 | 0.77 | NOS3 (0.32) | NOS3NOS1NOS2 | |
| SCHEMBL25910823 | 0.76 | NOS3 (0.33) | NOS3NOS1NOS2 | |
| SCHEMBL25910824 | 0.75 | NOS3 (0.35) | NOS3NOS1NOS2P2RX3P2RX2 | |
| SCHEMBL25951870 | 0.75 | — | — | |
| SCHEMBL25910820 | 0.75 | CYP3A4 (0.35) | NOS3NOS1NOS2 | |
| SCHEMBL18722041 | 0.72 | NOS3 (0.41) | NOS3NOS1NOS2P2RX3P2RX2 | |
| SCHEMBL21161269 | 0.72 | — | — | |
| SCHEMBL30068288 | 0.72 | P2RX3 (0.36) | NOS3NOS1NOS2P2RX3P2RX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226114-A1 | INHIBITORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| WO-2024073587-A1 | N-ACRYLOYLMORPHOLINE DERIVATIVES AS KEAP1 MODULATORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226114-A1 | INHIBITORS AND USES THEREOF | KEAP1, NQO1, NFE2L2 | NOS3 1318/4885NOS1 1279/4885NOS2 1075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.